Dupilumab outcomes in pediatric asthma by early eosinophil status: Post hoc analysis of VOYAGE/EXCURSION.
J Allergy Clin ImmunolJun 30, 2026 (epub)
Sharon Dell, Theresa W Guilbert, Antoine Deschildre et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of the randomized controlled trials VOYAGE and EXCURSION evaluated the long-term efficacy and safety of dupilumab in children aged 6 to 11 with type 2 asthma, focusing on those with early increases in blood eosinophils. The study found that dupilumab significantly reduced exacerbation rates and improved lung function and asthma control, with 22.4% of participants showing eosinophil levels ≥500 cells/μL at week 12.
Key findings
- Dupilumab reduced exacerbation rates versus placebo during VOYAGE, with effects maintained in EXCURSION.
- 22.4% of children had ≥500 eosinophils/μL at VOYAGE week 12.
- Improvements in lung function and asthma control were observed in both subgroups with and without early eosinophil increases.
- No safety differences were noted across subgroups.
Why it matters
Understanding the impact of dupilumab on asthma management in children, particularly regarding eosinophil levels, is crucial for optimizing treatment strategies and improving patient outcomes in pediatric asthma.